Frontiers in Oncology (Jun 2021)
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies
- Maria B. Garcia-Fabiani,
- Maria B. Garcia-Fabiani,
- Santiago Haase,
- Santiago Haase,
- Andrea Comba,
- Andrea Comba,
- Stephen Carney,
- Stephen Carney,
- Brandon McClellan,
- Brandon McClellan,
- Kaushik Banerjee,
- Kaushik Banerjee,
- Mahmoud S. Alghamri,
- Mahmoud S. Alghamri,
- Faisal Syed,
- Faisal Syed,
- Padma Kadiyala,
- Padma Kadiyala,
- Felipe J. Nunez,
- Marianela Candolfi,
- Antonela Asad,
- Nazareno Gonzalez,
- Marisa E. Aikins,
- Marisa E. Aikins,
- Anna Schwendeman,
- Anna Schwendeman,
- James J. Moon,
- James J. Moon,
- James J. Moon,
- Pedro R. Lowenstein,
- Pedro R. Lowenstein,
- Maria G. Castro,
- Maria G. Castro
Affiliations
- Maria B. Garcia-Fabiani
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Maria B. Garcia-Fabiani
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Santiago Haase
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Santiago Haase
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Andrea Comba
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Andrea Comba
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Stephen Carney
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Stephen Carney
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Brandon McClellan
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Brandon McClellan
- Immunology graduate program, University of Michigan Medical School, Ann Arbor, MI, United States
- Kaushik Banerjee
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Kaushik Banerjee
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Mahmoud S. Alghamri
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Mahmoud S. Alghamri
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Faisal Syed
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Faisal Syed
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Padma Kadiyala
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Padma Kadiyala
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Felipe J. Nunez
- Leloir Institute Foundation, Buenos Aires, Argentina
- Marianela Candolfi
- Instituto de Investigaciones Biomédicas (INBIOMED, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
- Antonela Asad
- Instituto de Investigaciones Biomédicas (INBIOMED, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
- Nazareno Gonzalez
- Instituto de Investigaciones Biomédicas (INBIOMED, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
- Marisa E. Aikins
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, United States
- Marisa E. Aikins
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States
- Anna Schwendeman
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, United States
- Anna Schwendeman
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States
- James J. Moon
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, United States
- James J. Moon
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States
- James J. Moon
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States
- Pedro R. Lowenstein
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Pedro R. Lowenstein
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Maria G. Castro
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Maria G. Castro
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- DOI
- https://doi.org/10.3389/fonc.2021.631037
- Journal volume & issue
-
Vol. 11
Abstract
High grade gliomas are malignant brain tumors that arise in the central nervous system, in patients of all ages. Currently, the standard of care, entailing surgery and chemo radiation, exhibits a survival rate of 14-17 months. Thus, there is an urgent need to develop new therapeutic strategies for these malignant brain tumors. Currently, immunotherapies represent an appealing approach to treat malignant gliomas, as the pre-clinical data has been encouraging. However, the translation of the discoveries from the bench to the bedside has not been as successful as with other types of cancer, and no long-lasting clinical benefits have been observed for glioma patients treated with immune-mediated therapies so far. This review aims to discuss our current knowledge about gliomas, their molecular particularities and the impact on the tumor immune microenvironment. Also, we discuss several murine models used to study these therapies pre-clinically and how the model selection can impact the outcomes of the approaches to be tested. Finally, we present different immunotherapy strategies being employed in clinical trials for glioma and the newest developments intended to harness the immune system against these incurable brain tumors.
Keywords
